Patient time requirements for anticoagulation therapy with warfarin

Medical Decision Making

Volumn 30, Issue 2, 2010, Pages 206-216

  Jonas, Daniel E ^a   Bryant Shilliday, Betsy ^a,b   Laundon, W Russell ^b   Pignone, Michael ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

Anticoagulation; Health economics; Human capital method; Time; Warfarin

Indexed keywords

ANTICOAGULANT AGENT; WARFARIN;

ADULT; AGED; ARTICLE; COST; DRUG MONITORING; ECONOMICS; FEMALE; HEALTH ECONOMICS; HUMAN; MALE; MIDDLE AGED; SOCIOECONOMICS; TIME;

ADULT; AGED; AGED, 80 AND OVER; ANTICOAGULANTS; COSTS AND COST ANALYSIS; DRUG MONITORING; ECONOMICS, MEDICAL; FEMALE; HUMANS; MALE; MIDDLE AGED; SOCIOECONOMIC FACTORS; TIME FACTORS; WARFARIN;

EID: 77950620909     PISSN: 0272989X     EISSN: 1552681X     Source Type: Journal    
DOI: 10.1177/0272989X09343960     Document Type: Article

References (48)

1. AHRQ announces guide to help patients on Coumadin®/war farin therapy. Available from: http://www.ahrq.gov/research/jul08/0708RA1.htm
2. Gold MR, Siegel JE, Russell LB, Weinstein MC, eds. Cost-Effectiveness in Health and Medicine. New York: Oxford University Press ; 1996.
3. Russell LB, Gold MR, Siegel JE, Daniels N., Weinstein MC The role of cost-effectiveness analysis in health and medicine. Panel on Cost-Effectiveness in Health and Medicine. JAMA. 1996 ; 276: 1172-1177.
4. Siegel JE, Weinstein MC, Russell LB, Gold MR Recommendations for reporting cost-effectiveness analyses. Panel on Cost-Effectiveness in Health and Medicine. JAMA. 1996 ; 276: 1339-1341.
5. Weinstein MC, Siegel JE, Gold MR, Kamlet MS, Russell LB Recommendations of the Panel on Cost-Effectiveness in Health and Medicine. JAMA. 1996 ; 276: 1253-1258.
6. Jonas DE, Russell LB, Sandler RS, Chou J., Pignone M. Patient time requirements for screening colonoscopy. Am J Gastroenterol. 2007 ; 102: 2401-2410.
7. Jonas DE, Russell LB, Sandler RS, Chou J., Pignone M. Value of patient time invested in the colonoscopy screening process: time requirements for colonoscopy study. Med Decis Making. 2008 ; 28: 56-65.
8. Lafata JE, Martin SA, Kaatz S., Ward RE The cost-effectiveness of different management strategies for patients on chronic warfarin therapy. J Gen Intern Med. 2000 ; 15: 31-37. (Pubitemid 30060936)
9. Connock M., Stevens C., Fry-Smith A., et al. Clinical effectiveness and cost-effectiveness of different models of managing long-term oral anticoagulation therapy: a systematic review and economic modelling. Health Technol Assess. 2007 ; 11: iii - iv, ix - 66.
10. Jowett S., Bryan S., Murray E., et al. Patient self-management of anticoagulation therapy: a trial-based cost-effectiveness analysis. Br J Haematol. 2006 ; 134: 632-639.
11. Pignone M., Levin B. Recent developments in colorectal cancer screening and prevention. Am Fam Physician. 2002 ; 66: 297-302. (Pubitemid 34810082)
12. Frew E., Wolstenholme JL, Whynes DK Willingness-to-pay for colorectal cancer screening. Eur J Cancer. 2001 ; 37: 1746-1751.
13. Frew E., Wolstenholme JL, Atkin W., Whynes DK Estimating time and travel costs incurred in clinic based screening: flexible sigmoidoscopy screening for colorectal cancer. J Med Screen. 1999 ; 6: 119-123.
14. Safford MM, Russell L., Suh DC, Roman S., Pogach L. How much time do patients with diabetes spend on self-care ? J Am Board Fam Pract. 2005 ; 18: 262-270.
15. Whynes DK, Frew E., Wolstenholme JL A comparison of two methods for eliciting contingent valuations of colorectal cancer screening. J Health Econ. 2003 ; 22: 555-574.
16. Potisek NM, Malone RM, Shilliday BB, et al. Use of patient flow analysis to improve patient visit efficiency by decreasing wait time in a primary care-based disease management programs for anticoagulation and chronic pain: a quality improvement study. BMC Health Serv Res. 2007 ; 7: 8.
17. Davis TC, Long SW, Jackson RH, et al. Rapid estimate of adult literacy in medicine: a shortened screening instrument. Fam Med. 1993 ; 25: 391-395.
18. Phelps CE Health Economics. 3 rd ed. Boston: Addison Wesley ; 2003.
19. Bureau of Labor Statistics. National Compensation Survey. June 2006. Available from: http://www.bls.gov/ncs/ncspubs-2006.htm
20. Ansell J., Hirsh J., Hylek E., et al. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8 th edition). Chest. 2008 ; 133 (suppl). 160S - 198S. (Pubitemid 351892967)
21. Hirsh J., Fuster V., Ansell J., Halperin JL American Heart Association/American College of Cardiology Foundation guide to warfarin therapy. Circulation. 2003 ; 107: 1692-1711. (Pubitemid 36397341)
22. Agency for Healthcare Research and Quality. Your Guide to Coumadin®/Warfarin Therapy. AHRQ Pub. No. 08-0028-A. Rockville, MD: Agency for Healthcare Research and Quality ; 2008. Available from: http://www.ahrq.gov/ consumer/coumadin.htm
23. The Role of Vitamin K and COUMADIN Use [brochure]. New York: Bristol-Myers Squibb Company ; 2008. Available from: http://www.coumadin.com/ pdf/293US08WA03002-v9-VitaminKBro-8.5x11.pdf
24. Selden CR, Zorn M, Ratzan SC, Parker RM, eds. National Library of Medicine Current Bibliographies in Medicine: Health Literacy. Bethesda, MD: National Institutes of Health, US Department of Health and Human Services ; 2000. Pub. No. CBM 2000-1. Available from: http://www.nlm.nih.gov/archive// 20061214/pubs/cbm/hliteracy.html
25. CMS Manual System National Coverage Determinations. 2008. Publication 100-3, Transmittal 90. Available from: http://www.cms.hhs.gov/Transmittals/ Downloads/R90NCD.pdf
26. Heneghan C., Alonso-Coello P., Garcia-Alamino JM, et al. Self-monitoring of oral anticoagulation: a systematic review and meta-analysis. Lancet. 2006 ; 367: 404-411.
27. Taborski U., Wittstamm FJ, Bernardo A. Cost-effectiveness of self-managed anticoagulant therapy in Germany. Semin Thromb Hemost. 1999 ; 25: 103-107.
28. Muller E., Bergemann R. ; GELIA Study Group. Economic analysis of bleeding and thromboembolic sequelae after heart valve replacement (GELIA 7). Eur Heart J Suppl. 2001 ; 3: Q65-9.
29. de Solà-Morales Serra O., Elorza Ricart JM Portable coagulometers: a systematic review of the evidence on self-management of oral anticoagulant treatment [in Spanish]. Med Clin (Barc). 2005 ; 124: 321-325.
30. Regier DA, Sunderji R., Lynd LD, Gin K., Marra CA Cost-effectiveness of self-managed versus physician-managed oral anticoagulation therapy. CMAJ. 2006 ; 174: 1847-1852.
31. Ansell JE, Hamke AK, Holden A., Knapic N. Cost effectiveness of monitoring warfarin therapy using standard versus capillary prothrombin times. Am J Clin Pathol. 1989 ; 91: 587-589.
32. Cantor SB, Levy LB, Cardenas-Turanzas M., et al. Collecting direct non-health care and time cost data: application to screening and diagnosis of cervical cancer. Med Decis Making. 2006 ; 26: 265-272.
33. Mandelblatt JS, Lawrence WF, Womack SM, et al. Benefits and costs of using HPV testing to screen for cervical cancer. JAMA. 2002 ; 287: 2372-2381.
34. Shireman TI, Tsevat J., Goldie SJ Time costs associated with cervical cancer screening. Int J Technol Assess Health Care. 2001 ; 17: 146-152.
35. Bech M., Gyrd-Hansen D. Cost implications of routine mammography screening of women 50-69 years in the county of Funen, Denmark. Health Pol. 2000 ; 54: 125-141.
36. Secker-Walker RH, Vacek PM, Hooper GJ, Plante DA, Detsky AS Screening for breast cancer: time, travel, and out-of-pocket expenses. J Natl Cancer Inst. 1999 ; 91: 702-708.
37. Bryan S., Buxton M., McKenna M., Ashton H., Scott A. Private costs associated with abdominal aortic aneurysm screening: the importance of private travel and time costs. J Med Screen. 1995 ; 2: 62-66.
38. Lawrence WF, Peshkin BN, Liang W., et al. Cost of genetic counseling and testing for BRCA1 and BRCA2 breast cancer susceptibility mutations. Cancer Epidemiol Biomarkers Prev. 2001 ; 10: 475-481.
39. Stringer M. Personal costs associated with high-risk prenatal care attendance. J Health Care Poor Underserved. 1998;9:222-35. 40. Attard NJ, Zarb GA, Laporte A. Long-term treatment costs associated with implant-supported mandibular prostheses in edentulous patients. Int J Prosthodont. 2005;18:117-23.
40. Cromwell J., Bartosch WJ, Fiore MC, Hasselblad V., Baker T. Cost-effectiveness of the clinical practice recommendations in the AHCPR guideline for smoking cessation. Agency for Health Care Policy and Research. JAMA. 1997 ; 278: 1759-1766.
41. Robbins JM, Tilford JM, Gillaspy SR, et al. Parental emotional and time costs predict compliance with respiratory syncytial virus prophylaxis. Ambul Pediatr. 2002 ; 2: 444-448.
42. Russell LB, Ibuka Y., Carr D. How much time do patients spend on outpatient visits? The American Time Use Survey. Patient. 2008 ; 1: 211-222.
43. Salome HJ, French MT, Miller M., McLellan AT Estimating the client costs of addiction treatment: first findings from the client drug abuse treatment cost analysis program (Client DATCAP). Drug Alcohol Depend. 2003 ; 71: 195-206.
44. Sculpher M., Palmer MK, Heyes A. Costs incurred by patients undergoing advanced colorectal cancer therapy: a comparison of raltitrexed and fluorouracil plus folinic acid. Pharmacoeconomics. 2000 ; 17: 361-370.
45. Yabroff KR, Warren JL, Knopf K., Davis WW, Brown ML Estimating patient time costs associated with colorectal cancer care. Med Care. 2005 ; 43: 640-648.
46. Stringer M., Ratcliffe SJ, Evans EC, Brown LP The cost of prenatal care attendance and pregnancy outcomes in low-income working women. J Obstet Gynecol Neonatal Nurs. 2005 ; 34: 551-560.
47. Whitney CW, Milgrom P., Conrad D., Fiset L., OHara D. The relationship between price of services, quality of care, and patient time costs for general dental practice. Health Serv Res. 1997 ; 31: 773-790.
48. Juster FT, Stafford, FP The allocation of time: empirical findings, behavioral models, and problems of measurement. J Econ Lit. 1991 ; 29: 471-522.